- Home
- UNCY vs SLGL Comparison
UNCY vs SLGL Comparison
Compare UNCY & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UNCY | SLGL |
|---|---|---|
| Founded | 2016 | 1997 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 141.8M | 159.7M |
| IPO Year | 2021 | 2016 |
Fundamental Metrics
Financial Performance| Metric | UNCY | SLGL |
|---|---|---|
| Price | $6.92 | $89.15 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | $44.50 | ★ $110.00 |
| AVG Volume (30 Days) | ★ 601.6K | 14.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 56.25 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $675,000.00 | N/A |
| Revenue This Year | N/A | $122.71 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.45 | $0.40 |
| 52 Week High | $7.57 | $92.00 |
Technical Indicators
Market Signals| Indicator | UNCY | SLGL |
|---|---|---|
| Relative Strength Index (RSI) | 56.96 | 71.42 |
| Support Level | $5.90 | $32.56 |
| Resistance Level | $7.43 | N/A |
| Average True Range (ATR) | 0.34 | 8.01 |
| MACD | 0.04 | 1.37 |
| Stochastic Oscillator | 90.10 | 91.19 |
Price Performance
Historical ComparisonAbout UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.